Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Moutouh-de Parseval, L. A., Pickard, M. D., Sandor, V., Robert, C., & Flaherty, K. T. (2018). overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 19(10), 1315–1327. http://access.bl.uk/ark:/81055/vdc_100070083379.0x000018